Have you ever sat in a waiting room after a hard appointment and realized the hardest part was not the scan itself, but the silence that followed? That stretch between visits is where bills pile up, questions multiply, and people get lost. I keep coming back to that gap because it explains why a young cancer care company just pulled in a nine-figure check and crossed a valuation that would have sounded ambitious only a year ago.
Why This Raise Matters Far Beyond One Startup
Thyme Care has closed a 125 million Series E round at a valuation of more than 2 billion. The round was led by Morgan Health, with Humana and CVS Health Ventures joining a group that also includes AlleyCorp, HealthQuest Capital, and a16z Bio + Health. In plain terms, the company roughly doubled its last private mark in less than a year.
That is not just a headline number. It is a bet that the messy middle of oncology, the phone calls, the prior authorizations, the “who do I call on a Sunday” moments, can be turned into a scalable service. Launched in 2020, the firm built a virtual navigation platform for people living with cancer. Coverage now reaches more than 10.5 million people across all 50 U.S. states. It manages more than 7 billion dollars in oncology spend. Revenue last year passed 125 million, five times the year before. Those figures are the kind of operating proof investors usually wait years to see.
When we started this business six years ago, we had this vision that we needed to go after all the white spaces that were being constantly overlooked in oncology.
– Robin Shah, co-founder
Shah co-founded the company with chief medical officer Bobby Green. He stepped down as chief executive in July and named Brad Diephuis, the former president and chief operating officer, as CEO. Shah now serves as executive chairman of a new parent, Thyme Companies. I find that structure more interesting than the funding itself. The operating business is no longer the whole story. The parent is meant to spawn more companies around the same core problem: how cancer care is delivered, accessed, and paid for.
The Quiet Crisis Between Appointments
Oncology has better drugs than it did a decade ago. Survival curves have moved. Imaging is sharper. And yet a diagnosis still feels like being dropped into a maze with no map. Clinics are packed. Specialists are scarce. Insurance language is its own dialect. Families become project managers overnight.
Thyme Care’s pitch is simple on paper and hard in practice. Stay with the patient in the spaces between visits. Answer the questions that never make it onto the exam-room clock. Coordinate the next step before a small delay becomes a missed cycle of treatment. That “care in between” is where a lot of cost and a lot of heartbreak hide.
In my experience watching healthcare startups, the ones that last do not try to replace the oncologist. They try to make the oncologist’s plan actually happen. Navigation sounds soft until you measure no-shows, abandoned regimens, and emergency visits that could have been a phone call two days earlier.
- Coverage across every U.S. state for more than 10.5 million people
- More than 7 billion dollars in oncology spend under management
- Revenue above 125 million last year, five times the prior year
- Positive free cash flow and a larger balance sheet for new bets
Those are not vanity metrics if they hold. Managing spend at that scale means the company sits close to health plans and providers, not just consumers with an app. That positioning is why strategic investors from the payer and pharmacy worlds showed up for this round.
A New Parent Company And A Broader Ambition
Thyme Companies is the vehicle for the next chapter. Shah described it as a platform to build other initiatives, even full companies, aimed at overlooked oncology problems. The first two themes are not mysterious. One is drug affordability. The other is clinical trial access.
Perhaps the most interesting aspect is the timing. The core navigation business is now profitable, according to the company, and generating positive free cash flow. That changes the conversation. Three years ago, every extra project would have competed with survival. Now the firm can hire, acquire, and experiment without betting the whole shop on one product line.
Diephuis is meant to keep Thyme Care humming. Shah is meant to look sideways at adjacent markets. That split can fail if the parent becomes a slide-deck holding company. It can work if the first new businesses ship something real later this year, which is the timeline the team has floated.
Why Biosimilars Still Feel Like A Broken Promise
Cancer drugs are among the most expensive therapies in medicine. Biosimilars were supposed to act like generics for complex biologics: clinically equivalent, cheaper, widely adopted. In many oncology categories, the savings have been thinner and slower than patients were led to expect.
Shah’s argument is blunt. The products exist. The discount is not reliably landing where it should. Thyme Companies wants to work with health plans and providers to push meaningful adoption of lower-cost biosimilars. That is less about inventing a molecule and more about unsticking the market: contracting, education, workflow, and incentives that still favor the originator brand.
I have found that affordability work succeeds only when someone owns the last mile. A formulary change on a slide does not change what a practice infuses on Tuesday morning. If a navigator or a dedicated commercial unit can pair clinical equivalence data with a cleaner prior-auth path and a clear patient bill, adoption can move. If not, everyone nods at the savings and keeps ordering the familiar brand.
| Focus area | What is broken today | What a new unit could change |
| Biosimilars | Savings lag behind the promise | Plan and provider workflows that actually switch |
| Trial access | Enrollment is slow and uneven | Navigation that matches patients to open studies |
| Care gaps | Questions pile up between visits | Virtual teams that stay on the case |
| Spend control | Oncology costs keep climbing | Scale already managing billions in spend |
None of this is glamorous. It is operational. That is usually a compliment in healthcare. The companies that quietly reroute money and time tend to last longer than the ones that only talk about a new interface.
Clinical Trials Need Guides, Not Just Protocols
Ask any trial sponsor what keeps them up at night and enrollment will be near the top of the list. Sites struggle to find the right patients. Patients struggle to find the right sites. Eligibility criteria read like a locked door. Geography still decides too much. Under-enrollment delays drugs that might help the next cohort of people sitting in those waiting rooms.
Thyme Companies wants to improve access and navigation inside that world. The logic is almost obvious once you have a national navigation network. If you already talk to patients across diagnoses, stages, and ZIP codes, you can spot trial-eligible people earlier. You can explain the process in human language. You can reduce the drop-off between “maybe this study” and “first screening visit.”
Will that be easy? No. Trials are regulated, fragmented, and politically sensitive. Sponsors guard data. Sites guard workflow. Patients guard hope. A new business in this lane has to earn trust on all three sides. Still, the mismatch is so large that even a modest improvement in match rates would matter for both patients and development timelines.
Enrollment challenges are limiting patient access to beneficial trials and slowing drug development.
– Company leadership on the trial bottleneck
The first of the new businesses is expected later this year. That is soon enough to be a real test, not a five-year vision slide.
What The Valuation Actually Says
A jump past 2 billion after a 125 million raise is aggressive in a market that has punished healthcare stories that grow revenue without a path to cash. This one claims both growth and free cash flow. If that combination is durable, the multiple starts to look less like fashion and more like a scarce asset: a scaled navigator sitting on billions of oncology dollars with payer relationships already in the room.
Strategic money from Humana and CVS Health Ventures is a signal as much as it is capital. Payers and pharmacy-linked investors do not usually show up for a cute patient app. They show up when a vendor can change utilization, site of care, or drug mix. Morgan Health leading the round points in the same direction. This is an industrial healthcare story wearing a consumer-friendly name.
Does that mean the price is “right”? Nobody outside the cap table can answer that with a straight face. Private marks move. Public markets can be colder. Shah said there is no near-term viewpoint on an IPO, only a willingness to look at public or private capital if it helps the company move faster. That is the correct public answer. It is also, frankly, the only answer that does not box a board in.
- Confirm that cash generation holds as new businesses launch.
- Watch whether biosimilar work produces measurable savings, not just meetings.
- See if trial navigation can enroll people without creating noise for sites.
- Track whether acquisitions add capability or just complexity.
- Judge whether the parent structure clarifies ownership or blurs it.
Leadership Handoff Without A Victory Lap
Founder-to-operator transitions are where a lot of high-growth companies get sloppy. Shah saying Diephuis had already been a major driver of the business is the kind of line you hear in every polished announcement. The more useful tell is the timing. The step-down happened in July. The raise and the parent company arrived after the new CEO was already in the chair. That sequence suggests the board wanted operating continuity before expanding the map.
Green remaining as chief medical officer matters more than people outside oncology usually admit. Navigation products live or die on clinical credibility. If oncologists think a vendor is guessing, they ignore it. If they think the medical leadership understands toxicity, staging, and the difference between a delay that is annoying and a delay that is dangerous, they will take the calls.
Recruiting is also on the table, along with acquisitions. A large balance sheet after a profitable stretch is a different tool kit than a large balance sheet after a desperate stretch. The first can be patient. The second shops in a panic. I would rather see this team buy a narrow capability, a trial-matching engine, a specialty pharmacy workflow, a regional navigation book, than announce a vague “platform play.”
The Human Scale Behind The Spreadsheet
It is easy to talk about 10.5 million covered lives and forget that each one is a person trying to keep a job, a marriage, a sense of humor. Cancer care is expensive, yes. It is also lonely. People leave appointments with a printout and a head full of terms they will Google at 1 a.m. A good navigator is part traffic controller, part translator, part persistent friend who actually calls back.
That is why the “care in between” phrase sticks. Appointments are scheduled. Life is not. Side effects show up on weekends. Prior authorizations stall on Tuesdays. A family member wants to know if a second opinion is worth the drive. Those are not exotic problems. They are the texture of treatment. Solve enough of them and you change outcomes without inventing a new drug.
I do not think every white space in oncology should become a startup. Some gaps belong to clinics, some to public policy, some to basic decency. But the ones that sit at the intersection of logistics, payment, and patient fear are commercial for a reason. Someone has to staff the phones. Someone has to stitch the data. Someone has to argue with a plan about a biosimilar that is sitting on the shelf while the originator keeps winning by inertia.
What the next 18 months should prove: Navigation stays profitable while the parent expands Biosimilar work shows dollar savings, not just intent Trial matching produces enrollments, not brochures Culture survives the founder’s shift to the parent
How Investors Are Reading Oncology Right Now
Oncology remains one of the largest and most frustrating spend categories in American healthcare. New therapies arrive with breathtaking price tags. Community practices feel squeezed. Academic centers run complex trials and still lose patients to confusion. Employers stare at cancer line items and wonder which vendor is theater and which vendor is plumbing.
Navigation companies have had a mixed decade. Some were care-management theater with a nice script. Some were call centers with a medical veneer. The ones that earned a second look tied themselves to risk, to total cost of care, or to a specific bottleneck like oral oncolytics or site-of-care shifts. Thyme Care’s claim is that it already sits on enough spend and enough geographic coverage to be taken seriously on those terms.
Five-times revenue growth in a year is the sort of number that makes people squint. Fast ramps can mean product-market fit. They can also mean a contract wave that is hard to repeat. The honest read is that both can be true at once. The Series E is a chance to professionalize the next layer before the growth rate normalizes, as growth rates always do.
Strategic investors add another wrinkle. They can open doors. They can also create channel conflict if the company ever wants to work with every plan and every pharmacy benefit manager in the market. So far the roster looks like a coalition, not a single-payer captive. That is healthier, at least on paper.
What Could Go Wrong, Without The Drama
Plenty. Navigation quality can slip when you scale. Nurses and guides burn out. Health plans can squeeze vendors after the pilot glow fades. Biosimilar campaigns can stall if manufacturers of originator products fight harder than expected. Trial tools can annoy sites if they send poorly screened candidates. A parent company can distract the core team that actually makes the money.
There is also the simple risk of trying to solve too many white spaces at once. Shah’s original instinct, go after the overlooked parts of oncology, is still the right instinct. The danger is treating every overlooked part as a company. Some problems are features. Some are new firms. Knowing the difference is the whole job of an executive chairman with a fresh holding structure.
Regulation will hover in the background. Anything that touches utilization, drug choice, or trial matching will attract questions about incentives. That is fair. Patients should not be steered toward a cheaper product if it is the wrong product, or toward a trial if standard care is clearly better for that person. Credibility is a wasting asset. Spend it once on a sloppy steer and clinicians will not return your emails.
A Note On Speed Versus Stay Power
Shah said the team is focused on being together for the long term, with a hyperfocus on oncology. That line would be filler if the company were still burning cash and chasing a story. Coming from a business that says it is already cash-flow positive, it reads more like a preference than a pitch. They can afford to move in years, not quarters, at least for now.
Still, capital has a way of creating its own clock. A 2 billion-plus mark invites comparison. Employees will want to know what the next liquidity path looks like even if the official line is “no near-term IPO view.” Partners will ask whether the parent will compete with them. Rivals will try to hire the same navigators. Speed and stay power are not enemies, but they argue in the same kitchen.
My own view is mildly old-fashioned. I would rather this group ship one sharp biosimilar program and one clean trial-navigation service than announce six logos by spring. Healthcare already has enough holding companies with pretty names. It does not have enough teams that make Tuesday afternoon easier for a person on treatment.
What Patients And Plan Sponsors Should Watch
If you live with a diagnosis, the test is practical. Do you get a human who knows your chart? Do authorizations move? Does someone notice when you miss a refill? Fancy corporate architecture will not impress you if the phone tree gets worse.
If you run benefits for an employer or a plan, the test is different. Can the vendor show avoided acute care, faster time to treatment, and a cleaner drug mix without hiding the methodology? Can they do it in more than one region? Can they keep doing it after the implementation team leaves?
- Time from diagnosis or referral to first definitive treatment
- Emergency and inpatient use during active therapy
- Biosimilar adoption where clinically appropriate
- Trial screening volume and actual enrollments
- Member-reported confusion between visits
Those measures are imperfect. They are still better than applause for a funding round. Money is an input. Relief is an output.
The Bigger Pattern In Cancer Care Businesses
Look around the category and a pattern shows up. The science keeps leaping. The system that delivers the science keeps limping. That mismatch is the opening for navigation, specialty pharmacies, second-opinion networks, home infusion, and now, if this parent company is serious, affordability and trial access units that behave like products rather than white papers.
It is tempting to call all of this disruption. I would call most of it unfinished plumbing. Disruption is a word that photographs well. Plumbing is what keeps a household from flooding. Oncology does not need another manifesto. It needs fewer people falling through the cracks between a great academic paper and a Tuesday infusion chair.
That is why this raise landed with more weight than a typical late-stage healthcare round. The company is not asking the market to imagine a future customer. It is asking the market to fund the next layer on top of a book of business that already spans the country. Imagination is cheap. Coverage in fifty states is not.
A Closing Thought That Is Not A Bow
Six years is not a long time in cancer care and it is a lifetime in startup years. The founders started with a bet that the overlooked spaces were the real product. Investors just paid a 2 billion-plus price to keep that bet going, and to let it branch.
Will biosimilars finally deliver the savings people were promised? Will trial navigation get the right person to the right study before the window closes? Will the core service stay kind at scale? Those questions are more useful than the valuation headline, even if the headline is what brought you here.
I keep picturing that waiting room. The scan is done. The hallway is too bright. Somebody should call before the fear hardens into delay. If a well-funded company can make that call reliably, for millions of people, the cap table will have been the least interesting part of the story. If it cannot, no parent company name will save it. That is the standard that matters, and it is the standard this next chapter has to meet.
